Updates on Primary Prevention of Cervical Cancer through Vaccination
July 18, 2019 • 4:00 - 5:00 PM (Eastern)
There is new information on HPV Vaccination including changes in the ages of recommendation and changes in view of other cancer prevention including head and neck cancer. There is population based data from other countries that have ramificaitons for US providers and patients. Additionally, there are new understandings on the immune mechanisms behind HPV vaccines.
Mark H. Einstein, MD, MS
Mark H. Einstein, MD, MS, Professor and Chair, Department of Obstetrics, Gynecology, & Women’s Health and Assistant Dean, Clinical Research Unit at Rutgers New Jersey Medical School. Dr. Einstein is an internationally-renowned expert in Gynecologic Oncology, particularly for his clinical and research focus in cervical cancer and Human Papillomavirus (HPV). Clinically, he manages complicated gynecologic malignancies and surgery and reconstruction for complex gynecologic cancers and related conditions. His primary research interests focus on the pathogenesis, therapy, and prevention of cervical cancer. Dr. Einstein has developed and has been leading numerous multi-institutional clinical trials in targeting HPV and cervical cancer as well as cervical cancer prevention. He has been active in translating clinical trial and translational data into clinical practices regarding cervical cancer prevention including being a 1) member of the Steering Committee for the American Society for Colposcopy and Cervical Pathology (ASCCP) Cervical Screening and Management Guidelines, 2) workgroup member of the American Cancer Society and the Society of Gynecologic Oncologists separate recommendations for HPV vaccines as well as 3) a consultant to the World Health Organization (WHO), developing their modules on the immunologic basis of HPV vaccines, and harmonizing with current cervical cancer screening. He is the president-elect of the ASCCP.
This activity is intended for physicians, physician assistants, midwives, nurse practitioners, nurses working in obstetrics and gynecology, gynecology oncology, oncology, internal medicine, family medicine and general practice.
Upon completion of this educational activity, participants should be able to:
- Describe updates on immune basis of HPV vaccination
- Discuss updated recommendations for HPV vaccination
- Discuss head and neck cancer prevention
As an accredited provider of CME credit, ASCCP has implemented a process to ensure that anyone who is in a position to affect the content of an educational activity has disclosed all relevant financial relationships with any commercial interest. Any conflicts of interest have been resolved by ASCCP prior to the activity.
The following person(s) disclosed relevant financial relationships:
- Mark H. Einstein, MD, MS – Faculty – AstraZeneca (Grant), Pfizer (Grant), Inovio (Grant), Papivax (Consultant), PDS Biotechnologies (Consultant), Cynvec (Consultant), BD Diagnostics (Consultant), Altum Pharma (Consultant)
The following person(s) disclosed no relevant financial relationships:
- Elizabeth A. Kostas-Polston, PhD, APRN, WHNP - Education Committee Co-Chair
- Peter F. Schnatz, DO - Education Committee Co-Chair
- Kerry Curtis - Staff
- Cate Langley - Staff
- Cari Price - Staff
- Alisha Yocum - Staff
This webinar is partially supported by an independent education grant from BD Diagnostics.
Continuing Medical Education (CME)
ASCCP is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA PRA Category 1 Credit(s)TM
ASCCP designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.